8legs: Natera, inc.

Your Followed Topics

#1 out of 2

Natera Executive Chairman Matthew Rabinowitz sold 200,000 shares in multiple March 2026 transactions.
Total proceeds from the sales reached about $38.28 million.
Post-sale, Rabinowitz directly owns 2,310,772 shares and indirectly 5,000 through spousal ownership.
Sales were conducted at weighted average prices within specified ranges.
The filings are documented in Form 4 disclosures with the SEC.
TradingView provided the AI-powered summary of the insider trade.
Rabinowitz remains a significant Natera holder after the sale.
No details on future trading plans were provided in the summary.
The article cites March 12 to March 16, 2026 as the sale window.
Investors are advised to verify information with the official SEC filings.

Vote 0

#2 out of 2

Natera’s oncology testing momentum is building amid growing demand for its assays.
The company cites enrollment and commercial traction driving the uptrend in oncology tests.
Analysts see expanding clinical utility and payer support as factors behind growth.
The discussion frames a favorable long-term outlook for Natera’s oncology portfolio.
The piece notes the clinical and commercial drivers behind the momentum.
Tumor profiling's evolving landscape is highlighted as underpinning growth.
The report implies payer support could broaden access to Natera’s tests.
Commercial traction is cited as a key driver behind the momentum.
The piece suggests a favorable near- and long-term outlook for the stock’s oncology segment.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.